SPY342.73-0.65 -0.19%
DIA281.97-0.98 -0.35%
IXIC11,484.69-31.80 -0.28%

Morgan Stanley Maintains Overweight on Acceleron Pharma, Raises Price Target to $125

Morgan Stanley maintains Acceleron Pharma (NASDAQ:XLRN) with a Overweight and raises the price target from $123 to $125.

· 10/13/2020 08:08
Morgan Stanley maintains Acceleron Pharma (NASDAQ:XLRN) with a Overweight and raises the price target from $123 to $125.